Eli Lilly's Oral GLP-1 Foundayo Shows Significant Improvement in Sleep Apnea Phase 3 Trial
Eli Lilly (LLY) has announced positive results from its Phase 3 ATTAIN-OSA study regarding the oral GLP-1 receptor agonist, Foundayo (orforglipron). The clinical trial demonstrated that participants treated with Foundayo experienced significant improvements in obstructive sleep apnea symptoms over a 52-week period. The data suggests that Foundayo could provide a therapeutic alternative or adjunct for patients struggling with sleep apnea. As an oral medication, it offers a different delivery mechanism compared to injectable GLP-1 therapies, potentially expanding the accessibility and utility of Lilly's metabolic drug portfolio.
Tickers: $LLY
Topics: Drug Development GLP-1 Phase 3 Trial Sleep Apnea
Read the full article at Seeking Alpha
Part of the story Eli Lilly's Foundayo Obesity Pill Shows Significant Reduction in Sleep Apnea Severity (2 articles)